Disc Medicine enters September with a fresh analyst upgrade pulling in one direction and options traders turning more defensive than they've been in weeks — an unusual split for a biotech that has barely moved on the week.
The most newsworthy development this week is from the Street. Wedbush raised its price target on IRON to $100 from $88 on September 2, maintaining its Outperform rating. That follows HC Wainwright lifting its target to $120 in early August and Morgan Stanley nudging its Overweight target to $85 in June. The analyst consensus is uniformly constructive — every recent move has been a raise or a reiterate, with no downgrades — and the mean price target of $102.58 implies roughly 30% upside from the current $78.67 close. Bulls point to promising Phase 2 data on selcodebart for anemia in myelofibrosis and chronic kidney disease, a Roche collaboration, and an expected FDA end-of-Phase 2 meeting before year-end. Bears flag that the pipeline remains early-stage, profitability is years away, and the near-term PV data readout due in Q3 2026 carries binary risk.
Options positioning complicates the bullish analyst narrative. The put/call ratio has moved more defensively than usual, running at 0.42 — about 1.5 standard deviations above its 20-day average of 0.33. That is not an extreme reading, but the direction is clear: over the past two weeks the PCR has climbed steadily from below 0.30. Demand for downside protection has risen even as the stock held relatively flat on the week, down 4.5% to $78.67. The 52-week PCR range is wide — 0.02 to 2.61 — so current levels are nowhere near a panic read, but the drift higher is worth noting.
Short positioning has been stable, and the borrow market is not signalling any pressure. Short interest ticked up about 1.5% on the week to 19.4% of the free float — still elevated for a biotech of this size, but off the higher levels seen in early August when it briefly crossed 20% of float. Borrow costs remain low at 0.56%, and availability is comfortable at 336%, meaning there is more than three times as much lending supply as there are shares currently borrowed. The ORTEX short score has eased slightly from a peak of 73.4 to 72.8 over the past week — still firmly elevated at the 8th percentile of the short-score universe — but the trend has flattened rather than accelerated. This is a persistently shorted name, not one where the short community is actively pressing new positions right now.
The activist register is worth carrying as context. OrbiMed Advisors filed a Schedule 13D/A in March 2025 disclosing a 4.5% stake, and AI DMI LLC holds 8.0% on a 13D filing last updated in October 2025 — down from a prior 10.8%, suggesting that position has been trimmed. As with all 13D/G disclosures, stakes are as-last-reported around the 5% threshold; holders who fall below that level may not file again. The most recent COO insider activity — a paired option exercise and sale under a pre-arranged 10b5-1 plan on August 25 — is compensation mechanics rather than a conviction signal, and marks a meaningful shift from the pattern flagged last week when CEO and COO sales were the dominant insider story.
Institutional flow adds one interesting data point. JP Morgan Asset Management added nearly 497,000 shares in the most recently reported quarter, and T. Rowe Price added 326,000 — the two largest incremental buys among the top holders. FMR (Fidelity) remains the largest holder at 12.7% but trimmed slightly. The top-15 holders collectively hold a large portion of the float, which combined with a 19.4% short interest figure means the free float available for trading is genuinely constrained. Earnings are next due on October 30 — the last three prints produced single-digit-percentage moves in both directions, with no clear pattern — making the catalyst calendar the next natural focus point after the FDA meeting timeline.
The next thing to watch is whether the Wedbush target raise draws fresh institutional interest or whether the options market's drift toward caution proves the more prescient read ahead of the Q3 PV data readout.
See the live data behind this article on ORTEX.
Open IRON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
